Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study - 09/01/20
, Kang Sun, PhD b, Maria K. Hordinsky, MD cAbstract |
Background |
There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects.
Objective |
To assess the efficacy and safety of 1.5% ruxolitinib cream in patients with AA who had at least 25% hair loss by Severity of Alopecia Tool score.
Methods |
This was a 2-part study. Part A was an open-label, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 99% hair loss followed by a 24-week extension period. Part B was a double-blind, vehicle-controlled, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 100% hair loss, followed by a crossover to ruxolitinib cream in the vehicle group for 24 weeks and additional treatment time for the ruxolitinib cream group.
Results |
Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth based on 50% improvement in Severity of Alopecia Tool scores between patients receiving 1.5% ruxolitinib cream and vehicle in part B. There were no significant safety issues with 1.5% ruxolitinib cream.
Limitations |
Single strength of ruxolitinib cream.
Conclusions |
The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.
Le texte complet de cet article est disponible en PDF.Key words : alopecia areata, clinical trial, ruxolitinib cream
Abbreviations used : AA, AT, AU, IL, JAK, PGARG, SALT, SALT50, SALT90
Plan
| Funding sources: Supported by Incyte Corporation. |
|
| Disclosure: Dr Olsen has served as a consultant and investigator for Aclaris and as a consultant for Bioniz, Incyte, Lilly, and Pfizer. She did not receive any compensation from Incyte in writing this article. Drs Kornacki and Sun are employees and stockholders of Incyte Corporation. Dr Hordinsky has served as a consultant for Incyte, Concert, and Bioniz and as an investigator for Incyte, Aclaris, Lilly, and Pfizer. |
|
| IRB approval status: Protocol approved by the IRB or independent ethics committee at each study site; informed consent forms were obtained from each study participant. |
|
| Reprints not available from the authors. |
Vol 82 - N° 2
P. 412-419 - février 2020 Retour au numéro
Article précédent
- Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review
- Sean Igelman, Anastasia O. Kurta, Umar Sheikh, Ashley McWilliams, Eric Armbrecht, Stephanie R. Jackson Cullison, Douglas W. Kress, Anna Smith, Leslie Castelo-Soccio, James Treat, William D. Boothe, Lucia Z. Diaz, Moise L. Levy, Avni Patel, Lara Wine Lee, M. Carmen Fraile-Alonso, Richard J. Antaya, Sonal Shah, Nicole Kittler, Lisa Arkin, Elaine Siegfried
- Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins
- Emily Stamell Ruiz, Shlomo A. Koyfman, Syril Keena T. Que, Jason Kass, Chrysalyne D. Schmults
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?